Entrectinib in NTRK fusion-positive, locally advanced or metastatic solid tumours and metastatic, ROS1-positive non-small cell lung cancer
Entrectinib has shown efficacy in the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor kinase ( NTRK ) fusion-positive, locally advanced or metastatic solid tumours who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies, and for the treatment of people with metastatic, ROS1-positive non-small cell lung cancer ( NSCLC ).
An integrated analysis was carried out on data of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials, and data from the phase I/Ib STARTRK-NG study.
The integrated analysis included data from 53 people with ROS1-activating gene fusions and 54 people with locally advanced or metastatic NTRK fusion-positive solid tumours ( 10 tumour types, more than 19 histopathologies ) from the phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials.
Data from the phase I/Ib STARTRK-NG study in paediatric patients were also included.
The studies enrolled people across 15 countries and more than 150 clinical trial sites. Tumour types evaluated in the studies to date included breast, cholangiocarcinoma, colorectal, gynaecological, neuroendocrine, non-small cell lung, salivary gland, pancreatic, sarcoma and thyroid cancers.
STARTRK-2 is a phase II, global, multicentre, open-label basket study in people with solid tumours that harbour an NTRK1/2/3, ROS1 or ALK-positive gene fusion.
The primary endpoint is objective response rate ( ORR ), and duration of response ( DoR ) is a secondary endpoint. Other secondary outcome measures include time to response, clinical benefit rate, intracranial tumour response, progression-free survival ( PFS ), central nervous system ( CNS ) PFS and overall survival ( OS ).
STARTRK-1 is a phase I, multicentre, open-label dose escalation study of a daily continuous dosing schedule in people with solid tumours with NTRK1/2/3, ROS1 or ALK gene fusions in the US and South Korea.
The trial assessed the safety and tolerability of Entrectinib via a standard dose escalation scheme and determined the recommended phase II dose.
ALKA-372-001 is phase I, multicentre, open-label dose escalation study of an intermittent and continuous Entrectinib dosing schedule in people with advanced or metastatic solid tumours with TRKA/B/C, ROS1 or ALK gene fusions in Italy.
STARTRK-NG is a phase I/II dose-escalation and expansion study evaluating the safety and efficacy of Entrectinib in children and adolescent patients with no curative first-line treatment option, recurrent or refractory extracranial solid tumours or primary CNS tumours, with or without TRK, ROS1 or ALK fusions.
Results from the integrated analysis have shown Entrectinib shrank tumours ( ORR ) in more than half ( 57.4% ) of people with NTRK fusion-positive solid tumours.
Objective responses to Entrectinib were seen across 10 different solid tumour types ( median DoR = 10.4 months ), including in people with and without CNS metastases at baseline.
In these studies, Entrectinib shrank tumours that had spread to the brain in more than half of people ( intracranial response [ IC ORR ] = 54.5% ), with more than a quarter of these people having a complete response.
Entrectinib shrank tumours in 77.4% of people with locally advanced or metastatic ROS1-positive NSCLC.
In addition, Entrectinib has demonstrated a durable response of more than two years ( median DoR = 24.6 months ).
Importantly, Entrectinib was shown to shrink intracranial tumours in more than half of people with CNS metastases at baseline ( IC ORR = 55.0% ).
The safety profile of Entrectinib was consistent with that seen in previous analyses.
The most commonly reported adverse reactions included fatigue, constipation, altered sense of taste ( dysgeusia ), swelling ( edema ), dizziness, diarrhea, nausea, nervous system disorders ( dysesthesia ), shortness of breath ( dyspnea ), pain, anemia, cognitive disorders, weight increased, vomiting, cough, blood creatinine increase, joint pain ( arthralgia ), fever ( pyrexia ), and muscle pain ( myalgia ).
Entrectinib is an investigational, oral medicine for the treatment of locally advanced or metastatic solid tumours that harbour NTRK1/2/3 or ROS1 gene fusions.
It is a selective tyrosine kinase inhibitor designed to inhibit the kinase activity of the TRK A/B/C and ROS1 proteins, whose activating fusions drive proliferation in certain types of cancer.
Entrectinib can block ROS1 and NTRK kinase activity and may result in the death of cancer cells with ROS1 or NTRK gene fusions.
NTRK fusion-positive cancer
Neurotrophic tyrosine receptor kinase ( NTRK ) fusion-positive cancer occurs when the NTRK1/2/3 genes fuse with other genes, resulting in altered TRK proteins ( TRKA/TRKB/TRKC ) that can activate signaling pathways involved in proliferation of certain types of cancer.
NTRK gene fusions are tumour-agnostic, meaning they are present in tumours irrespective of site of origin.
These fusions have been identified in a broad range of solid tumour types, including breast, cholangiocarcinoma, colorectal, gynaecological, neuroendocrine, non-small cell lung, salivary gland, pancreatic, sarcoma and thyroid cancers.
ROS1 is a tyrosine kinase, which plays a role in controlling how cells grow and proliferate. When a ROS1 gene fusion occurs, cancer cells grow and proliferate in an uncontrolled manner. Blocking this abnormal signalling can cause tumour cells to shrink or die.
ROS1 gene fusions account for 1-2% of NSCLC. Young never-smokers with NSCLC have the highest incidence of ROS1 gene fusions. ( Xagena )
Source: Roche, 2019